Trial Profile
A Single Arm Study to Assess the Sustained Virological Suppression and Improvement of Treatment-emerged Adverse Events of Switching to Raltegravir in Stable HIV-infected Patients on Ritonavir-boosted Protease Inhibitor Regimen
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms TaISENWITCH
- 14 Sep 2016 Status changed from recruiting to completed.
- 13 Sep 2012 New trial record